Glaxo Wellcome, Inc. v. Impax Laboratories, Inc.
Federal Circuit (January 29, 2004)

Court found that the doctrine of equivalents did not apply (prosecution history estoppel–Glaxo amended claims to recite the critical term HPMC in order to overcome a rejection for lack of enablement).

“Because Glaxo cannot prove infringement literally or under the doctrine of equivalents, this court affirms the United States District Court for the Northern District of California” which ruled that IMPAX’s generic product did not infringe Glaxo’s patent for the antidepressant Wellbutrin SR.

Copy of case here.

Copy of Impax press release here.

Related posts:

1. Dr. Harry Gaus v. Conair Corporation (Fed.Cir.)
2. Glaxo Group Limited, et al. v. Apotex, Inc. (Fed. Cir.)